AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 171 min read$ELVN

ORBIMED ADVISORS LLC sold $12.7M of ELVN (indirect holdings)

ORBIMED ADVISORS LLC sold 281,408 indirectly-held shares of Enliven Therapeutics, Inc. (ELVN) at $45.02 ($12.67M total) across 2 trades on 2026-06-15.

Original reporting
SEC EDGAR · ORBIMED ADVISORS LLC
Published Jun 17, 2026, 11:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ELVN
Bearish
medium confidence
Mentioned
$ELVN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNBearishLow
01

Why it matters

The newest disclosed fact is the $12.67M open-market sale executed 2026-06-15, which can influence short-term sentiment and positioning.

02

Market read

Traders may reassess near-term sentiment/flow dynamics in ELVN based on a sizable 10%-owner sale, but there is no accompanying fundamental update.

03

What to watch

Indirect holdings and the lack of a stated 10b5-1 plan can amplify speculation; traders should check for other concurrent insider transactions or subsequent filings for confirmation.

Relevance 7/10Novelty 8/10Timing: filed 2026-06-17; sale executed 2026-06-15

Background

SEC Form 4 reports an insider transaction by ORBIMED ADVISORS LLC (10% owner) in Enliven Therapeutics, Inc. (ELVN).

Company-level read

Ticker impact

$ELVNBearishMedium confidence
Context

ORBIMED ADVISORS LLC, a 10% owner, sold 281,408 ELVN shares in open-market transactions on 2026-06-15 for ~$12.67M.

Expected impact

Slight-to-moderate downside bias over days, with limited follow-through unless additional disclosures emerge.

Evidence & confidence

The filing is primary (Form 4) and sizable, but it does not indicate company-specific negative news; absence of a stated 10b5-1 plan increases interpretive risk for traders.

Market effects

Sector

No direct sector read-through; this is an ownership/positioning signal for a single biotech name.

Regional

None indicated beyond US small/mid-cap biotech sentiment.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be routine liquidity/portfolio rebalancing by an indirect holder; without a 10b5-1 plan, it still may not reflect a bearish view on ELVN fundamentals.

Key entities

  • issuer
    Enliven Therapeutics, Inc.

    ELVN; subject of the Form 4 insider transaction.

  • 10% owner
    ORBIMED ADVISORS LLC

    Reported indirect open-market sale of ELVN shares; not indicated as a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ELVN insider trading history →

Related articles

OCT 8
$ELVNMedAI 8/10

Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment

Guggenheim reiterated a Buy rating and $78 price target for Enliven Therapeutics (ELVN) after FDA alignment on its Phase 3 study design for relcobatinib. The stock is down 10.5% this week but up 169% YTD. Multiple analysts have initiated coverage with positive ratings and price targets ranging from $70 to $78. The Phase 3 trial will enroll 450 patients and is set to start by year-end 2026.

investing.com2 min
OCT 6
$ELVNMedAI 8/10

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven Therapeutics (ELVN) reached FDA agreement on the Phase 3 trial design for relcobatinib (ELVN-001) in treating chronic myeloid leukemia. The ENABLE-2 trial will compare relcobatinib to second-generation TKIs, with a target enrollment of 450 patients. The company plans to initiate the trial by year-end 2026.

prnewswire.com2 min
OCT 1
$ELVNMed

Enliven Therapeutics stock initiated at Overweight by JPMorgan

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.

investing.com2 min